Policy & Regulations

This channel includes news coverage of healthcare policy and regulations set by Congress, the states, Centers for Disease Control and Prevention (CDC), the Department of Health and Human Services (HHS), U.S. Food and Drug Administration (FDA), and medical associations and societies. 

RSS icon
Thumbnail

Net prices of drugs have jumped 60% since 2007

The prices of prescription drugs have risen 60% over an 11-year period, as have discounts that widen medical gaps, according to a new study published in JAMA.

Thumbnail

$8.3B package for coronavirus approved

Congress approved an $8.3 billion package to fight the spread of coronavirus and respond to the growing crisis.

Thumbnail

FTC receives support––and pushback––for interfering in hospital merger

The healthcare industry has voiced its support and pushback after the FTC sued to block a merger between two hospital systems in Philadelphia.

Thumbnail

Supreme Court will take up ACA lawsuit

The Supreme Court will listen to the legal challenge to the Affordable Care Act that has been working its way through the lower courts. The court made its decision to hear the case Monday, March 2.

Thumbnail

FTC plans to kill a hospital merger

The FTC is moving to block a proposed merger between Jefferson Health and Einstein Healthcare Network, two Philadelphia-based health systems. The two entities have a combined annual revenue of $5.9 billion.

HHS mitigates coronavirus risks, asks for $2.5B in funding

The Trump administration recently asked Congress for $2.5 billion in funding to address the outbreak of the disease as the number of cases continues to grow worldwide.

Thumbnail

CMS may increase accreditation control

CMS Administrator Seema Verma is once again putting pressure on Medicare accrediting organizations that certify healthcare providers for reimbursement under the federal healthcare program.

Thumbnail

UnitedHealth’s stock just had its worst day in 9 years

UnitedHealth Group saw its worst stock day in nearly 9 years on Feb. 24, with shares dropping 7.8%, according to MarketWatch.

Displaying 801 - 808 of 2773

Around the web

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup